Hair loss on a GLP-1 has mostly been explained as a side effect of losing weight quickly, not of the drug itself. A study published on 3 September 2026 suggests that, for one kind of hair loss in men, the drug's own activity may play a part too.
It is a careful piece of genetics, and it has been passed around this month as "GLP-1 drugs cause significant hair loss in men". The study does not say that. Here is what it does say.
What happened
Researchers at NYU Langone Health, led by Lynn Petukhova, PhD, published their findings online in the Journal of Investigative Dermatology on 3 September (PubMed 42692190). They used a method called two-sample Mendelian randomization.
The idea is simple. Some people are born with small variations in their genes that give them naturally higher levels of the GLP-1 receptor, the protein that Ozempic, Wegovy, Mounjaro and Zepbound act on. Genes are handed out at conception, before diet, weight or medicine can get involved, so if those people turn out to have more of a condition, the receptor is a plausible cause rather than a coincidence.
- The stand-in for the drug: 22 gene variants that raise GLP-1 receptor expression in the blood, taken from the eQTLGen database of 31,684 people.
- The outcome: male-pattern hair loss (androgenetic alopecia), from a genetic dataset of 205,327 men.
- The result: men with genetically higher GLP-1 receptor activity had about a 7% added risk of male-pattern hair loss.
- What did not explain it: the figure held after the team accounted for high blood pressure, insulin resistance and testosterone, three known influences on hair loss.
The authors call it the first genetic evidence of a link between GLP-1 activity and male-pattern hair loss. It also hints that thinning on these medicines may not be only about weight loss: the receptor itself may affect the hair follicle.
What it did not find
Read the limits before you read the headline.
- Nobody in the study took a GLP-1. The gene variants are a model of the drugs, not the drugs. A lifelong, slightly higher receptor level is not the same as a weekly injection at a much higher dose, and the effect could be larger, smaller or different.
- Men only. The pattern hair-loss data is much larger for men, so women could not be tested. Nothing here says women are or are not affected.
- Mostly White, European-ancestry data. Both databases are, so the result may not carry over to everyone.
- No mechanism. The study suggests a cause; it does not show how the receptor would affect the follicle.
- A relative figure. 7% is added on top of a risk that is already common and mostly inherited. It is not 7 men in 100.
The study was funded by the National Institutes of Health. Two of the authors have run trials of hair-loss treatments, and one is a paid consultant to several companies, including Eli Lilly, which makes Mounjaro and Zepbound. Their disclosures are listed in the NYU Langone release.
Two kinds of hair loss, two different answers
This is the useful part. "Hair loss on a GLP-1" is two different things, and they need different responses.
| Shedding after fast weight loss | Male-pattern hair loss | |
|---|---|---|
| Medical name | Telogen effluvium | Androgenetic alopecia |
| What it looks like | Diffuse thinning all over, more hair in the brush and the shower | Receding temples, thinning at the crown |
| When | Two to four months after rapid loss | Gradual, over years |
| Does it come back? | Usually, once the trigger settles | Not on its own |
| Who | Anyone | Mainly men with a family history |
| What helps | Slower loss, enough protein, iron, zinc and B12 | Treatment from a doctor, started early |
| The evidence | The BMJ, 22 July 2026 | This study, 3 September 2026 |
The July study in The BMJ was about the first column: more recorded hair loss on a GLP-1, with fast weight loss and nutrient shortfalls as the likely cause. That kind is largely in your hands, through how quickly you lose and what you eat. This study is about the second column, which food does not reach.
A man can have both at once, and the first can make the second more noticeable.
What it means for you
If you are a man and pattern hair loss runs in your family, tell your prescriber before you start a GLP-1, or as soon as you notice your hairline or crown changing. Pattern hair loss responds best to treatment started early, and a dermatologist can usually tell the two kinds apart at one appointment.
If your hair is coming out all over the scalp a few months in, that is far more likely to be shedding after fast weight loss. Why shedding starts around month three, and what helps covers it in full.
Either way, do not stop or change your dose because of this study. It is one genetic study, and the benefits of the medicine for your weight and your health are measured in far larger ones.
And whatever your genes do, the shedding part is still about food. A GLP-1 switches off appetite; it does not switch off your need for protein, iron, zinc and B12. Hair is made of protein, and it is one of the first things the body stops making when intake runs short.
What to do with this
The part of hair loss you can control is the pace of your loss and the protein you eat. The calculator sets both from your weight and your dose.